# IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

> **NCT03753659** · PHASE2 · COMPLETED · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 30 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Pembrolizumab
- **PROCEDURE:** Radio Frequency Ablation (RFA)
- **PROCEDURE:** Microwave Ablation (MWA)
- **RADIATION:** Brachytherapy
- **DRUG:** Transarterial Chemoembolisation (TACE)

## Key facts

- **NCT ID:** NCT03753659
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-09
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03753659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03753659, "IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03753659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*